DNA vaccines: safety and efficacy issues
Springer Seminars in Immunopathology · 1997 · 19 (2) · 245-256
DOI: 10.1007/bf00870272 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Springer Seminars in Immunopathology, 1997. Verfasst von D M Klinman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Retroviral Immunology, Food and Drug Administration, Bethesda, MD 20892, USA. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
DNA technology has been harnessed to produce a variety of plasmid-based vaccines designed to prevent viral, bacterial and parasitic infections. The rapid adoption and implementation of this novel vaccine strategy carries with it important safety and efficacy concerns. This review will focus on whether DNA vaccines (1) are likely to induce systemic or organ-specific autoimmune disease, (2) have the potential to induce tolerance rather than immunity, and (3) are as effective in individuals with depressed immune function as they are in healthy adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Retroviral Immunology, Food and Drug Administration, Bethesda, MD 20892, USA.
Zitieren
APA
Klinman, D. M., Takeno, M., Ichino, M., Gu, M., Yamshchikov, G., Mor, G., & Conover, J. (1997). DNA vaccines: safety and efficacy issues. Springer Seminars in Immunopathology, 19(2), 245-256. https://doi.org/10.1007/bf00870272
Vancouver
Klinman DM, Takeno M, Ichino M, Gu M, Yamshchikov G, Mor G, et al. DNA vaccines: safety and efficacy issues. Springer Seminars in Immunopathology. 1997;19(2):245-256. doi:10.1007/bf00870272
BibTeX
@article{Klinman1997,
author = {Klinman, D M and Takeno, M and Ichino, M and Gu, M and Yamshchikov, G and Mor, G and Conover, J},
title = {DNA vaccines: safety and efficacy issues},
journal = {Springer Seminars in Immunopathology},
year = {1997},
volume = {19},
number = {2},
pages = {245--256},
doi = {10.1007/bf00870272}
}
EUVIMED